New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast

References

• Nestle FO Kaplan DH Barker J Psoriasis N Engl J Med 2009 361 5 496 509 19641206
   PubMed Web of Science ®Google Scholar
• Gottlieb AB Psoriasis: emerging therapeutic strategies Nat Rev Drug Discov 2005 4 1 19 34 15688070
   PubMed Web of Science ®Google Scholar
• Griffiths CE Barker JN Pathogenesis and clinical features of psoriasis Lancet 2007 370 9583 263 271 17658397
   PubMed Web of Science ®Google Scholar
• Gladman DD Psoriatic arthritis Dermatol Ther 2009 22 1 40 55 19222516
   PubMed Web of Science ®Google Scholar
• Chang CA Gottlieb AB Lizzul PF Management of psoriatic arthritis from the view of the dermatologist Nat Rev Rheumatol 2011 7 10 588 598 21912431
   PubMed Web of Science ®Google Scholar
• Myers WA Gottlieb AB Mease P Psoriasis and psoriatic arthritis: clinical features and disease mechanisms Clin Dermatol 2006 24 5 438 447 16966023
   PubMed Web of Science ®Google Scholar
• Melnikova I Psoriasis market Nat Rev Drug Discov 2009 8 10 767 768 19794440
   PubMed Web of Science ®Google Scholar
• Weger W Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents Br J Pharmacol 2010 160 4 810 820 20590580
   PubMed Web of Science ®Google Scholar
• Gottlieb A Korman NJ Gordon KB Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics J Am Acad Dermatol 2008 58 5 851 864 18423261
   PubMed Web of Science ®Google Scholar
• Korn T Bettelli E Oukka M Kuchroo VK IL-17 and Th17 Cells Annu Rev Immunol 2009 27 485 517 19132915
   PubMed Web of Science ®Google Scholar
• Leonardi C Matheson R Zachariae C Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis N Engl J Med 2012 366 13 1190 1199 22455413
   PubMed Web of Science ®Google Scholar
• Papp KA Langley RG Sigurgeirsson B Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study Br J Dermatol Epub 10 27 2012
   Google Scholar
• Papp KA Leonardi C Menter A Brodalumab, an anti- interleukin-17-receptor antibody for psoriasis N Engl J Med 2012 366 13 1181 1189 22455412
   PubMed Web of Science ®Google Scholar
• Garber K Anti-IL-17 mAbs herald new options in psoriasis Nat Biotechnol 2012 30 6 475 477 22678368
   PubMed Web of Science ®Google Scholar
• Gottlieb A Menter A Mendelsohn A Ustekinumab, a human inter-leukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial Lancet 2009 373 9664 633 640 19217154
   PubMed Web of Science ®Google Scholar
• Papp KA Langley RG Lebwohl M PHOENIX 2 study investigators Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 2008 371 9625 1675 1684 18486740
   PubMed Web of Science ®Google Scholar
• Leonardi CL Kimball AB Papp KA PHOENIX 1 study investigators Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 2008 371 9625 1665 1674 18486739
   PubMed Web of Science ®Google Scholar
• Goldminz AM Gottlieb AB Ustekinumab for psoriasis and psoriatic arthritis J Rheumatol Suppl 2012 89 86 89 22751602
   PubMedGoogle Scholar
• Gordon KB Langley RG Gottlieb AB A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis J Invest Dermatol 2012 132 2 304 314 22011907
   PubMed Web of Science ®Google Scholar
• Strober BE Crowley JJ Yamauchi PS Olds M Williams DA Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis Br J Dermatol 2011 165 3 661 668 21574984
   PubMed Web of Science ®Google Scholar
• Gottlieb AB Leonardi C Kerdel F Mehlis S Olds M Williams DA Efficacy and safety of briakinumab vs etanercept and placebo in patients with moderate to severe chronic plaque psoriasis Br J Dermatol 2011 165 3 652 660 21574983
   PubMed Web of Science ®Google Scholar
• Lin VW Ringold S Devine EB Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: a Bayesian network meta-analysis Arch Dermatol 2012 1 8
   Google Scholar
• Liu Y Wu EQ Bensimon AG Cost per responder associated with biologic therapies for Crohn’s disease, psoriasis, and rheumatoid arthritis Adv Ther 2012 29 7 620 634 22843208
   PubMed Web of Science ®Google Scholar
• Stanczyk J Ospelt C Gay S Is there a future for small molecule drugs in the treatment of rheumatic diseases? Curr Opin Rheumatol 2008 20 3 257 262 18388515
   PubMed Web of Science ®Google Scholar
• Bonilla-Hernán MG Miranda-Carús ME Martin-Mola E New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors Rheumatology (Oxford) 2011 50 9 1542 1550 21622522
   PubMed Web of Science ®Google Scholar
• Papp KA Menter A Strober B Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study Br J Dermatol 2012 167 3 668 677 22924949
   PubMed Web of Science ®Google Scholar
• Pfizer A one-year study to evaluate the effects and safety of CP-690,550 in patients with moderate to severe chronic plaque psoriasis ClinicalTrialsgov [website on the Internet] Bethesda, MD US National Library of Medicine 2011 [updated December 24, 2012]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01276639?term = tofacitinib + psoriasis &recr = Recruiting&phase = 2 & rank = 1. NLM identifier: NCT01276639Accessed February 8, 2013
   Google Scholar
• Fleischmann R Cutolo M Genovese MC Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs Arthritis Rheum 2012 64 3 617 629 21952978
   PubMed Web of Science ®Google Scholar
• Garber K Pfizer’s JAK inhibitor sails through phase 3 in rheumatoid arthritis Nat Biotechnol 2011 29 6 467 468 21654650
   PubMed Web of Science ®Google Scholar
• Maiga M Lun S Guo H Winglee K Ammerman NC Bishai WR Risk of tuberculosis reactivation with tofacitinib (CP-690550) J Infect Dis 2012 205 11 1705 1708 22474037
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company A study in participants with rheumatoid arthritis on background methotrexate therapy ClinicalTrialsgov [website on the Internet] Bethesda, MD US National Library of Medicine 2010 [updated September 18, 2012]. Available from http://www.clinicaltrials.gov/ct2/show/NCT01185353?term=baricitinib&rank=7. NLM identifier: NCT01185353Accessed February 8, 2013
   Google Scholar
• Conti M Beavo J Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling Annu Rev Biochem 2007 76 481 511 17376027
   PubMed Web of Science ®Google Scholar
• Houslay MD Schafer P Zhang KY Keynote review: phosphodiesterase-4 as a therapeutic target Drug Discov Today 2005 10 22 1503 1519 16257373
   PubMed Web of Science ®Google Scholar
• Page CP Spina D Phosphodiesterase inhibitors in the treatment of inflammatory diseases Handb Exp Pharmacol 2011 204 391 414 21695650
   PubMedGoogle Scholar
• Seldon PM Barnes PJ Meja K Giembycz MA Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase Mol Pharmacol 1995 48 4 747 757 7476903
   PubMed Web of Science ®Google Scholar
• Gobejishvili L Barve S Joshi-Barve S McClain C Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease Am J Physiol Gastrointest Liver Physiol 2008 295 4 G718 G724 18687753
   PubMed Web of Science ®Google Scholar
• Eigler A Siegmund B Emmerich U Baumann KH Hartmann G Endres S Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production J Leukoc Biol 1998 63 1 101 107 9469479
   PubMed Web of Science ®Google Scholar
• Platzer C Fritsch E Elsner T Lehmann MH Volk HD Prösch S Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells Eur J Immunol 1999 29 10 3098 3104 10540320
   PubMed Web of Science ®Google Scholar
• Essayan DM Huang SK Kagey-Sobotka A Lichtenstein LM Differential efficacy of lymphocyte- and monocyte-selective pretreat-ment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression J Allergy Clin Immunol 1997 99 1 Pt 1 28 37 9003208
   PubMed Web of Science ®Google Scholar
• Bos JD de Rie MA Teunissen MB Piskin G Psoriasis: dysregulation of innate immunity Br J Dermatol 2005 152 6 1098 1107 15948970
   PubMed Web of Science ®Google Scholar
• Schafer PH Parton A Gandhi AK Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis Br J Pharmacol 2010 159 4 842 855 20050849
   PubMed Web of Science ®Google Scholar
• Cameron AL Kirby B Fei W Griffiths CE Natural killer and natural killer-T cells in psoriasis Arch Dermatol Res 2002 294 8 363 369 12420105
   PubMed Web of Science ®Google Scholar
• Wagner EF Schonthaler HB Guinea-Viniegra J Tschachler E Psoriasis: what we have learned from mouse models Nat Rev Rheumatol 2010 6 12 704 714 20877306
   PubMed Web of Science ®Google Scholar
• Crilly A Robertson SE Reilly JH Phosphodiesterase 4 (PDE4) regulation of proinflammatory cytokine and chemokine release from rheumatoid synovial membrane Ann Rheum Dis 2011 70 6 1130 1137 21342916
   PubMed Web of Science ®Google Scholar
• McCann FE Palfreeman AC Andrews M Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis Arthritis Res Ther 2010 12 3 R107 20525198
   PubMed Web of Science ®Google Scholar
• Cherry JA Davis RL Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect J Comp Neurol 1999 407 2 287 301 10213096
   PubMed Web of Science ®Google Scholar
• Schafer P Apremilast mechanism of action and application to psoriasis and psoriatic arthritis Biochem Pharmacol 2012 83 12 1583 1590 22257911
   PubMed Web of Science ®Google Scholar
• ClinicalTrialsgov [webpage on the Internet] Search of: Apremilast -List Results Bethesda, MD US National Library of Medicine Available from: http://www.clinicaltrials.gov/ct2/results?term=Apremilast&Search=Search Accessed November 26, 2012
   Google Scholar
• Papp KA Kaufmann R Thaçi D Hu C Sutherland D Rohane P Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study J Eur Acad Dermatol Venereol Epub 10 3 2012
   Google Scholar
• Papp K Cather JC Rosoph L Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial Lancet 2012 380 9843 738 746 22748702
   PubMed Web of Science ®Google Scholar
• Schett G Wollenhaupt J Papp K Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study Arthritis Rheum 2012 64 10 3156 3167 22806399
   PubMed Web of Science ®Google Scholar
• Gottlieb AB Strober B Krueger JG An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast Curr Med Res Opin 2008 24 5 1529 1538 18419879
   PubMed Web of Science ®Google Scholar
• Burton PR Clayton DG Cardon LR Wellcome Trust Case Control Consortium; Australo-Anglo-American Spondylitis Consortium (TASC), Biologics in RA Genetics and Genomics Study Syndicate (BRAGGS) Steering Committee Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants Nat Genet 2007 39 11 1329 1337 17952073
   PubMed Web of Science ®Google Scholar
• Reveille JD Sims AM Danoy P Australo-Anglo-American Spondyloarthritis Consortium (TASC) Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci Nat Genet 2010 42 2 123 127 20062062
   PubMed Web of Science ®Google Scholar
• Pathan E Abraham S Van Rossen E Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis Ann Rheum Dis Epub 9 14 2012
   Google Scholar
• Schett G Hayer S Zwerina J Redlich K Smolen JS Mechanisms of disease: the link between RANKL and arthritic bone disease Nat Clin Pract Rheumatol 2005 1 1 47 54 16932627
   PubMedGoogle Scholar
• Kim HR Lee SH Kim HY Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS) Rheumatology (Oxford) 2006 45 10 1197 1200 16567356
   PubMed Web of Science ®Google Scholar
• ClinicalTrialsgov [webpage on the Internet] Search of: apremilast: Phase 3 - List Results Bethesda, MD US National Library of Medicine Available from: http://www.clinicaltrials.gov/ct2/results?term=apremilast&recr=&rslt=&type=&cond=&intr=&outc=&spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&phase=2&rcv_s=&rcv_e=&lup_s=&lup_e= Accessed November 26, 2012
   Google Scholar
• Samrao A Berry TM Goreshi R Simpson EL A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults Arch Dermatol 2012 148 8 890 897 22508772
   PubMedGoogle Scholar
• Paul J Foss CE Hirano SA Cunningham TD Pariser DM An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: A case series J Am Acad Dermatol 2013 68 2 255 261 22910104
   PubMed Web of Science ®Google Scholar
• Volf EM Au SC Dumont N Scheinman P Gottlieb AB A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis J Drugs Dermatol 2012 11 3 341 346 22395585
   PubMed Web of Science ®Google Scholar
• De Souza A Strober BE Merola JF Oliver S Franks AGJr Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study J Drugs Dermatol 2012 11 10 1224 1226 23134988
   PubMed Web of Science ®Google Scholar
• Bren L Psoriasis: more than cosmetic. FDA Consumer. 2004 Sept-Oct Available from: http://permanent.access.gpo.gov/lps1609/www.fda.gov/fdac/features/2004/504_psoriasis.html Accessed February 8, 2013
   Google Scholar